Follow the Chinese OTC omeprazole label's seven-day limit; difficulty swallowing, vomiting blood, or black stools require medical care
Omeprazole enteric-coated tablets became available without a prescription in China in 2022. The cited label limits self-treatment to seven days and says not to repeat it within two months. Do not self-treat if swallowing is difficult or painful, you vomit blood, or you pass bloody or black stools: these can signal a serious condition. Omeprazole can also mask stomach cancer symptoms and delay diagnosis.
What it takes
Nothing. Follow the duration stated on the label.
What you may gain
China's National Medical Products Administration switched omeprazole enteric-coated tablets from prescription-only to over-the-counter status in Announcement No. 68 of 2022, issuing a model label at the same time. The indication is short-term relief of heartburn and acid reflux caused by excess stomach acid. Precautions limit use to seven days and advise consulting a doctor or pharmacist if symptoms do not improve. The label prohibits another course within two months and calls for immediate medical assessment if symptoms recur. It advises against use when swallowing is difficult or painful, or there is vomiting of blood, blood in the stool, or black stool, because these may indicate a serious condition. Warning symptoms such as substantial unexplained weight loss, repeated vomiting, difficulty swallowing, vomiting blood, or black stool require malignancy to be excluded first, since treatment can conceal symptoms and delay diagnosis. People over 55 with new or changed symptoms should consult a doctor. People taking clopidogrel should avoid taking omeprazole at the same time.
Context & considerations
Clopidogrel helps prevent blood clots and is commonly prescribed after a stent or heart attack. Omeprazole can reduce its effect, so ask a clinician before combining them. The evidence is rated B because these are labeling requirements, without a study quantifying how many serious events following them prevents. The medium benefit rating is a judgment: the aim is to avoid delayed diagnosis of conditions such as gastrointestinal bleeding or stomach cancer, although most heartburn and reflux are not serious. The seven-day and two-month limits are from the cited Chinese OTC label; other countries and clinician-prescribed regimens may differ.
Research & references
China's National Medical Products Administration, Announcement on Switching Omeprazole Enteric-Coated Tablets from Prescription-Only to Over-the-Counter Status (No. 68 of 2022), Attachment 2, Model Over-the-Counter Label. https://www.nmpa.gov.cn/yaopin/ypggtg/20220826171517123.html